Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Research & Development Commercial Clinical Trials

Gelesis100 Reduces Insulin-Resistance in GLOW Obesity Trial

  • News

Executive Summary

Data from the pivotal GLOW trial presented at the Endocrine Society's annual meeting show that Gelesis' Gelesis100 non-systemic, superabsorbent hydrogel significantly reduces insulin-resistance compared to placebo in overweight and obese patients.

You may also be interested in...



Gelesis Presents Data Showing GS200, The Device That Looks Like A Drug, Treats Obesity

Results of the LIGHT UP study, which included prediabetic and diabetic subjects, could support FDA approval of GS200.

Gelesis's Plenity Obesity Product Earns De Novo For Wide BMI Range

PureTech's affiliate Gelesis has received US FDA de novo clearance for its Plenity capsule to treat overweight-obese adults, and plans to launch it commercially in the second half.

Gelesis Absorbs Clinical Affairs and Commercial Expertise With New Appointments

Gelesis reels in former Walgreens and Boehringer Ingelheim execs as it prepares to take its anti-obesity capsule-based treatment towards regulatory approvals.

Table

View full table

Topics

Tags:
Research & Development Commercial Clinical Trials
Latest Headlines

Why Investing In ESG Measures Is Good For Medtech’s Health And Sustainability

IVD DNA Test For Cancer Receives New Regulatory Classification

Minute Insight: Medtronic May Sell Respiratory And Monitoring Units To Private Equity

Stakeholders Give FDA An Earful; Poor Communication, Recall Inefficiency, Patients At Risk

See All
UsernamePublicRestriction

Register

MT124859

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By